Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Gerald Wolfgang Prager

19PUBLICATIONS
93CO-AUTHORS
Molecular targetsCancer cell biologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Environmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

Sort by Publication Date:
|Jun 25, 2026
Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

|Oct 08, 2025
Opportunities and Approaches to Optimising Advanced Cholangiocarcinoma Outcomes in the Era of Targeted Therapies: A Narrative Review.

Teresa Macarulla, Cindy Neuzillet, Gerald W Prager

|Sep 09, 2025
Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE.

Karin Potthoff, Jens Uhlig, Lutz Jacobasch

|Aug 29, 2025
Lack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single-center cohort.

Hannah C Puhr, Luzia Berchtold, Linda Zingerle

|Jul 11, 2025
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real-life worldwide population.

Federica Lo Prinzi, Francesca Salani, Silvia Camera

|May 19, 2025
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real-world results from a multicenter and multinational study.

Margherita Rimini, Lorenzo Fornaro, Federica Lo Prinzi

Pageof 4

Frequent Collaborators

4 joint publications

Anna S Berghoff

4 joint publications

Hannah C Puhr

4 joint publications

Matthias Preusser

3 joint publications

Julien Taieb

3 joint publications

Elisabeth S Bergen

3 joint publications

Sebastian Stintzing

3 joint publications

Teresa Macarulla Mercade

2 joint publications

Kathrin Heinrich

2 joint publications

Dominik Paul Modest

2 joint publications

Ellen Heitzer

Frequent Collaborators

4 joint publications

Anna S Berghoff

4 joint publications

Hannah C Puhr

4 joint publications

Matthias Preusser

3 joint publications

Julien Taieb